Oppenheimer analyst Matthew Biegler notes that Olema (OLMA) shares are up today, likely on news that Roche’s (RHHBY) evERA trial was a success. “No, that’s not the trial we’ve all been waiting for,” the firm says, but there may be some read-through. Most notably, Roche said that evERA hit in the intent-to-treat population, which means that giredestrant must have performed decently well in wild-type patients. That’s important for persevERA, Oppenheimer says. For that trial to work, giredestrant has to hold off the aromatase inhibitor long enough for patients to develop an ESR1 mutation – where it should have an advantage. Apparently, persevERA is being pushed back until Q1 2026, “so at least now you’ve got more time to do your homework on this potentially seismic readout,” adds the firm. Oppenheimer reiterates Buy rating on Olema with a price target of $22.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OLMA:
- Olema Pharmaceuticals: Strategic Positioning and Promising Outlook in the Oral SERD Market
- Oppenheimer says Olema collaboration with Pfizer could lead to bidding war
- Buy Recommendation for Olema Pharmaceuticals Driven by Strategic Collaborations and Promising Clinical Developments
- Strategic Collaboration with Pfizer Boosts Olema Pharmaceuticals’ Prospects in ER+ Breast Cancer Treatment
- Olema Pharmaceuticals Partners with Pfizer for New Trial